Article (Scientific journals)
The prospective screening for SARS-CoV-2 S1/S2 antibodies delineates the factual incidence of COVID-19 and shows a sustained serological response <i>post</i> COVID-19 in kidney transplant recipients
Firket, Louis; Bouquegneau, Antoine; Seidel, Laurence et al.
2022In Acta Clinica Belgica, p. 1-6
Peer Reviewed verified by ORBi
 

Files


Full Text
ACB_Firket_2022.pdf
Publisher postprint (1.62 MB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
General Medicine; Transplantation; COVID19; Serology; Epidemiology; Nephrology
Abstract :
[en] The impact of immunosuppression on the occurrence of Coronavirus Disease 2019 (COVID-19) remains unclear. We conducted a prospective screening of anti-S1/S2 IgGs against SARS-CoV-2 Spike protein from March, 1 2020 to May, 15 2021 (prior to the vaccination campaign) in a cohort of 713 kidney transplant recipients (KTRs). In a first phase, the factual incidence and seroprevalence of COVID-19 was established in this cohort: cases diagnosed by serology were added to RT-PCR-based diagnoses to obtain the overall incidence of COVID-19 in both symptomatic and asymptomatic KTRs. In the second phase, the kinetics of the post-COVID-19 humoral response were studied, taking into account the severity of the disease defined by the need for oxygen therapy (group S, "severe") or not (group nS, "not severe"). The combined diagnostic approaches identified 138 COVID-19 cases (19.2%), with 37 diagnoses by serology (26.8%). The rate of asymptomatic KTRs reached 20.3% (28/138). Thirteen patients (9.4%) died from COVID-19. The seroconversion rate was 91.7% (99/108). The peak anti-S1/S2 IgG level was 85 [30-150] AU/ml and was similar between the S and nS groups (117 [38; 186] AU/ml versus 73 [23; 140] AU/ml). A high probability of persistence of anti-S1/S2 IgG post-COVID-19 was observed, with only 10.1% (7/69) of the patients having negated their serology during the 9-month follow-up. In conclusion, our pragmatic serological screening combined with RT-PCR tests provides a better estimation of the real incidence of COVID-19 in KTRs. A significant proportion of KTRs develop humoral immunity post COVID-19, which most often persists beyond 9 months.
Disciplines :
Immunology & infectious disease
Author, co-author :
Firket, Louis ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de néphrologie
Bouquegneau, Antoine  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de néphrologie
Seidel, Laurence  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service des informations médico économiques (SIME)
BONVOISIN, Catherine ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de néphrologie
GROSCH, Stéphanie ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de néphrologie
Hayette, Marie-Pierre ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de microbiologie clinique
Jouret, François  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de néphrologie
WEEKERS, Laurent  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de néphrologie
Language :
English
Title :
The prospective screening for SARS-CoV-2 S1/S2 antibodies delineates the factual incidence of COVID-19 and shows a sustained serological response <i>post</i> COVID-19 in kidney transplant recipients
Publication date :
08 August 2022
Journal title :
Acta Clinica Belgica
ISSN :
1784-3286
eISSN :
2295-3337
Publisher :
Informa UK Limited
Pages :
1-6
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
ULiège - Université de Liège [BE]
Available on ORBi :
since 09 August 2022

Statistics


Number of views
91 (18 by ULiège)
Number of downloads
0 (0 by ULiège)

Scopus citations®
 
0
Scopus citations®
without self-citations
0
OpenCitations
 
0

Bibliography


Similar publications



Contact ORBi